Sodium–glucose co‐transporter 2 (SGLT2) inhibitors have recently been recommended as a
foundational therapy for patients with heart failure (HF) and reduced ejection fraction …

Research about heart failure (HF) has made major progress in the last years. We give here
an update on the most recent findings. Landmark trials have established new treatments for …

Background Three drug classes (mineralocorticoid receptor antagonists [MRAs], angiotensin
receptor–neprilysin inhibitors [ARNIs], and sodium/glucose cotransporter 2 [SGLT2] …

Despite guideline recommendations and available evidence, implementation of treatment in
heart failure (HF) is poor. The majority of patients are not prescribed drugs at target doses …

Члены Комитета экспертов подтвердили отсутствие финансовой поддержки/конфликта
интересов. В случае сообщения о наличии конфликта интересов, член (ы) Комитета …

Low blood pressure is common in patients with heart failure and reduced ejection fraction
(HFrEF). While spontaneous hypotension predicts risk in HFrEF, there is only limited …

Aims This study aimed to assess age‐and sex‐related differences in management and 1‐
year risk for all‐cause mortality and hospitalization in chronic heart failure (HF) patients …

Heart failure is increasing in prevalence, with approximately 26 million patients affected
worldwide. This represents a significant cause of morbidity and mortality. Statistics regarding …

Major changes have occurred in these last years in heart failure (HF) management.
Landmark trials and the 2021 European Society of Cardiology guidelines for the diagnosis …

Numerous guideline documents have issued recommendations to clinicians concerning the
treatment of chronic heart failure and a reduced ejection fraction. However, guidelines do …